Institutional Readiness for Management of COVID-19 Vaccine AstraZeneca in Trusts

Mark Cheeseman, Professional Lead for Medicines Information, Midlands & East, Midlands and East Medicines Advice Service (East site)Published Last updated See all updates

Must read guidance for Chief Pharmacists and others in Trusts on the COVID-19 Vaccine AstraZeneca.

Purpose

The attachment below outlines the medicines management responsibilities of Chief Pharmacists for Mass Vaccination in Hub and Non-Hub Trust sites, and provides supporting guidance and resources in relation to:

  • Safe storage and distribution, including temperature controlled storage, stock control and reporting vaccine usage to PHE
  • Oversight of vaccine handling and preparation

The document aims to promote consistency of practice by providing flow diagrams outlining a stepwise approach to implementing Pharmacy processes to receive, store and issue vaccines, and to oversee vaccine handling processes by clinical staff.

Attachments

Other handling content for Trusts

Other COVID-19 vaccines resources

What to do if you still have questions

If you still have questions you can get in touch with us. However, please first read our service remit; and if you still think we can help, use the email address below.

We're supporting healthcare professionals in England with pharmaceutical aspects of the COVID-19 vaccination programme; read our service remit to find out more.
If you're a healthcare professional in England, get in touch with us if you still have questions

Change history

  1. Addition of new link to IT Policy document on SPS website.
  2. Wording amended to clarify that outer packaging must be disposed of as confidential waste.
  1. Amended link for to best practice for storing COVID-19 vaccines in the refrigerator
  1. Minor amendment to wording linking to V1 IT Policy and removal of 'agent to be confirmed' for antiviral disinfectant.
  1. Quantity of vials in each carton corrected. Page numbers amended.
  1. Included hyperlink to ‘Deployment of COVID-19 Vaccine Oxford/AstraZeneca: implications for governance, handling and preparation of vaccines’ letter
  1. Published